iECURE, inc.

📍 Philadelphia, United States👥 27 employees💰 Last funded Feb 2023
Biotechnology🌐 iecure.com
Website LinkedIn
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania’s Gene Therapy Program. Using in vivo editing, our methods focus on inserting functioning genes into patients’ genomes, which offers long-term, stable expression of those genes. With our team’s proven track record, as well as the University of Pennsylvania’s deep expertise and translational genetic medicine engine, reversing the course of these devastating diseases is now within reach.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in iECURE, inc.?
iECURE, inc. has 1 investors on record on gritt.io.
When did iECURE, inc. last raise funding?
The most recent investment in iECURE, inc. recorded on gritt.io was in February 2023.
What industry is iECURE, inc. in?
iECURE, inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is iECURE, inc. based?
iECURE, inc. is headquartered in Philadelphia, United States.